MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s10557-026-07885-4

Медицинская библиотека · Cardiovascular drugs and therapy · 2026

Comparative Cardiovascular, Lipid, and Safety Effects of Lipid-Modifying Therapies in Diabetes: An Agent-, Class-, and Dose-Level Network Meta-Analysis.

Zhao Xudong, Zheng Shihao, Tang Cheng, Chen Jiafan, Shi Cuijuan, Yuan Tianqi, Liu Xiaoyu, Yang Ruigeng, Zhi Yushang, Wang Shidong

СтатьяСистематический обзорПеревод пока не подготовлен

Аннотация

AIMS: Comprehensive and fine-grained evidence of lipid-lowering drugs in patients with diabetes is lacking. This study aims to compare the efficacy and safety of lipid-modifying agents in this population across agent-, class-, and dose-levels.

METHODS

We systematically searched PubMed, Web of Science, Scopus, the Cochrane Central Register of Controlled Trials, Embase, and ClinicalTrials.gov from inception to October, 2025, for randomized controlled trials (RCTs) evaluating lipid-modifying therapies in patients with diabetes. A frequentist network meta-analysis was performed across multiple levels. Primary outcomes included major adverse cardiovascular events (MACE), stroke, myocardial infarction (MI), revascularization, cardiovascular death, and all-cause death. Secondary outcomes were lipid profile parameters. Safety outcomes were also assessed.

RESULTS

Eighteen RCTs involving 14 lipid-modifying agents and 89,717 participants were included. Statins, ezetimibe, PCSK9i and bempedoic acid each reduced the risk of MACE, with distinct agent-specific profiles across cardiovascular and lipid endpoints. Atorvastatin is associated with a strong reduction in multiple cardiovascular outcomes. Reduction in revascularization risk was specifically observed with atorvastatin at both moderate and high dose, while pravastatin was associated with a great reduction in stroke risk. Ezetimibe and evolocumab, with comparable efficacy, were associated with reductions in MI risk. PCSK9i significantly improved TC and LDL-C, while exerting mild effects on TG and HDL-C. Pemafibrate showed a pronounced benefit of TG-lowering efficacy. The renal safety of fibrates and bempedoic acid, and glycometabolism safety of EPA-DHA warrants monitoring.

CONCLUSION

Lipid-modifying therapies were associated with beneficial and specific cardiovascular and lipid effects in diabetes. The results provide more granular and tailored lipid management strategies.

TRIAL REGISTRATION: PROSPERO CRD420251163974.

Для цитирования: Zhao Xudong, Zheng Shihao, Tang Cheng, Chen Jiafan, Shi Cuijuan, Yuan Tianqi, Liu Xiaoyu, Yang Ruigeng, Zhi Yushang, Wang Shidong. Comparative Cardiovascular, Lipid, and Safety Effects of Lipid-Modifying Therapies in Diabetes: An Agent-, Class-, and Dose-Level Network Meta-Analysis.. Cardiovascular drugs and therapy. 2026. DOI: 10.1007/s10557-026-07885-4.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.